“…The clinical phenotype of 3q29del is heterogeneous, ranging from mild to moderate intellectual disability (ID) (Ballif et al, 2008; Cox & Butler, 2015; Glassford et al, 2016; Klaiman et al, 2022; Sanchez Russo et al, 2021; Willatt et al, 2005) to a 19-fold increased risk for autism spectrum disorder (ASD) (Itsara et al, 2009; Pollak et al, 2019; Sanders et al, 2015) and a greater than 40-fold increased risk for schizophrenia spectrum disorders (SZ) (Kirov et al, 2012; Marshall et al, 2017; Mulle, 2015; Mulle et al, 2010; Szatkiewicz et al, 2014). Recent work by our team has uncovered additional phenotypes associated with 3q29del, including attention deficit/hyperactivity disorder (ADHD) and graphomotor weakness (Klaiman et al, 2022; Pollak et al, 2023b; Sanchez Russo et al, 2021). Further, 47% of study participants were found to have clinically significant executive function deficits (Klaiman et al, 2022; Sanchez Russo et al, 2021).…”